drugset / Trial / NCT04152226
A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, single-dose, dose escalating evaluation of the safety and tolerability of three dose levels of DBI-001 in patients with Tinea pedis. The purpose of the current protocol is to establish the safety and tolerability of a single application of J. lividum to the feet of patients with proven T. pedis. In addition, the effect of J. lividum on the T. pedis will also be evaluated.
Timeline
- Start
- 2019-02-19
- Primary completion
- 2019-04-30
- Completion
- 2019-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Janthinobacterium lividum | Unknown | 1e+06 unknown | — |
| Comparator | Janthinobacterium lividum | Unknown | 1e+07 unknown | — |
| Comparator | Janthinobacterium lividum | Unknown | 1e+08 unknown | — |